May 26, 2020
Biosimilar Development
Over the last few years, stakeholders in the biosimilar field have urged the FDA to address common questions related to promotional labeling and advertisements for biosimilar and reference products. On Feb. 3, 2020, the FDA published Guidance for Industry on Promotional Labeling and Advertising Considerations for Prescription Biological Reference and Biosimilar Products addressing these common questions and provided recommendations for how to best develop and present promotional materials for biosimilars. In this article, Finnegan attorneys Brett Heavner and Kathryn Judson outline the central components of this new guidance as it relates to biologics labeling and promotional documents. While such materials are overseen by the FDA and governed by the laws within the Food, Drug and Cosmetic Act (FDCA), they also explore an alternative method of challenging claims of misinformation and other forms of unfair competition that may impact the biosimilar space moving forward.
Read the full article here.
Originally printed in Biosimilar Development on May 26, 2020. This article is for informational purposes, is not intended to constitute legal advice, and may be considered advertising under applicable state laws. This article is only the opinion of the authors and is not attributable to Finnegan, Henderson, Farabow, Garrett & Dunner, LLP, or the firm’s clients.
Workshop
Life Sciences Workshop: Updates and Key Trends in Pharmaceutical and Biotechnology IP Law
May 2, 2024
Cambridge
Ad Law Buzz Blog
“Banning” a Banned Ingredients Claim: NAD’s Application (and Expansion) of the FTC’s Green Guides
March 18, 2024
Webinar
February 15, 2024
Webinar
Hybrid Conference
7th Annual Legal, Regulatory, and Compliance Forum on Advertising Claims Substantiation
February 8-9, 2024
New York
Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.
We use cookies on this website to provide you with the best user experience. By accepting cookies, you agree to our use of cookies. Please note that if you opt not to accept or if you disable cookies, the “Your Finnegan” feature on this website will be disabled as well. For more information on how we use cookies, please see our Privacy Policy.
Finnegan is thrilled to announce the launch of our new blog, Ad Law Buzz, devoted solely to breaking news, developments, trends, and analysis in advertising law.